Nonquasiparticle states in half-metallic ferromagnets

Anomalous magnetic and electronic properties of the half-metallic ferromagnets (HMF) have been discussed. The general conception of the HMF electronic structure which take into account the most important correlation effects from electron-magnon interactions, in particular, the spin-polaron effects, is presented. Special attention is paid to the so called non-quasiparticle (NQP) or incoherent states which are present in the gap near the Fermi level and can give considerable contributions to thermodynamic and transport properties. Prospects of experimental observation of the NQP states in core-level spectroscopy is discussed. Special features of transport properties of the HMF which are connected with the absence of one-magnon spin-flip scattering processes are investigated. The temperature and magnetic field dependences of resistivity in various regimes are calculated. It is shown that the NQP states can give a dominate contribution to the temperature dependence of the impurity-induced resistivity and in the tunnel junction conductivity. First principle calculations of the NQP-states for the prototype half-metallic material NiMnSb within the local-density approximation plus dynamical mean field theory (LDA+DMFT) are presented.Comment: 27 pages, 9 figures, Proceedings of Berlin/Wandlitz workshop 2004; Local-Moment Ferromagnets. Unique Properties for Moder Applications, ed. M. Donath, W.Nolting, Springer, Berlin, 200

Open-label study of ademetionine for the treatment of intrahepatic cholestasis associated with alcoholic liver disease

BACKGROUND: The effect of oral and/or parenteral ademetionine (500 mg intravenous [IV] and tablet formulation) on clinical symptoms and biochemical markers of intrahepatic cholestasis (IHC) was investigated in subjects with alcoholic liver disease (ALD) and compensated liver function. METHODS: Prospective, multicenter, open-label study consisting of a screening period and an 8-week treatment period and performed in subjects (18-75 years) with compensated ALD and confirmed IHC. Subjects with a baseline serum coniugated bilirubin value above normal range were initially treated with IV ademetionine for two weeks (500-800 mg daily) and continued with oral ademetionine 1500 mg daily for a further six weeks. Subiects with a baseline serum coniugated bilirubin value within normal range were treated with oral ademetionine for eight weeks. RESULTS: A total of 72 subjects were treated; 41 initially with IV ademetionine and 31 with oral ademetionine. Clinical symptoms status improved from baseline to end of treatment with an increase in the proportion of subiects with no symptoms. Ademetionine showed significant improvements in primary efficacy parameters alkaline phosphatase (ALP) and y-glutamyltransferase (yGT) (P<0.0001). Although decreases of ALP were higher for subjects initially treated with IV ademetionine, these subjects also had higher baseline values. No safety concerns with ademetionine arose with respect to the severity or frequency of adverse events (AEs) during the treatment period, laboratory parameters, and vital signs. CONCLUSIONS: Administration of oral or IV/oral ademetionine step-therapy for 8 weeks to subjects with IHC due to ALD was safe and provided a significant improvement of disease burden. © 2018 EDIZIONI MINERVA MEDICA

Open-label study of ademetionine for the treatment of intrahepatic cholestasis associated with alcoholic liver disease

BACKGROUND: The effect of oral and/or parenteral ademetionine (500 mg intravenous [IV] and tablet formulation) on clinical symptoms and biochemical markers of intrahepatic cholestasis (IHC) was investigated in subjects with alcoholic liver disease (ALD) and compensated liver function. METHODS: Prospective, multicenter, open-label study consisting of a screening period and an 8-week treatment period and performed in subjects (18-75 years) with compensated ALD and confirmed IHC. Subjects with a baseline serum coniugated bilirubin value above normal range were initially treated with IV ademetionine for two weeks (500-800 mg daily) and continued with oral ademetionine 1500 mg daily for a further six weeks. Subiects with a baseline serum coniugated bilirubin value within normal range were treated with oral ademetionine for eight weeks. RESULTS: A total of 72 subjects were treated; 41 initially with IV ademetionine and 31 with oral ademetionine. Clinical symptoms status improved from baseline to end of treatment with an increase in the proportion of subiects with no symptoms. Ademetionine showed significant improvements in primary efficacy parameters alkaline phosphatase (ALP) and y-glutamyltransferase (yGT) (P<0.0001). Although decreases of ALP were higher for subjects initially treated with IV ademetionine, these subjects also had higher baseline values. No safety concerns with ademetionine arose with respect to the severity or frequency of adverse events (AEs) during the treatment period, laboratory parameters, and vital signs. CONCLUSIONS: Administration of oral or IV/oral ademetionine step-therapy for 8 weeks to subjects with IHC due to ALD was safe and provided a significant improvement of disease burden. © 2018 EDIZIONI MINERVA MEDICA

Results of treatment at an early stage of the postoperative period of patients with complicated forms of the syndrome of diabetic foot syndrome

Обстежено 113 хворих на синдром діабетичної стопи. Першій групі хворих проводили традиційне лікування, другій – традиційне лікування доповнювали гальванізацією нижніх кінцівок, третій – лікування поєднували з внутрішньотканинним електрофорезом берлітіону нижніх кінцівок. Сприятливіший перебіг та ефективність лікування відзначали у третій групі хворих. Оцінка ефективності лікування показала позитивний вплив на систему гемокоагуляції та фібринолізу, покращання динаміки цитологічної картини мазків-відбитків з ран, прискорене загоєння ран і зменшення їх бактеріальної забрудненості та зникнення локальних ознак запалення, скорочення кількості післяопераційних ускладнень та середнього терміну стаціонарного лікування. Обследовано 113 больных синдромом диабетической стопы. Первой группе больных проводили общепринятое лечение, второй – традиционное лечение дополняли гальванизацией нижних конечностей, в третьей – лечение дополняли внутритканевым электрофорезом берлитиона нижних конечностей. Наиболее благоприятное течение и эффективность лечения отмечали в третьей группе больных. Оценка эффективности лечения показала положительное влияние на систему гемокоагуляции и фибринолиза, улучшение динамики цитологической картины мазков-отпечатков с ран, более ускоренное заживление ран, уменьшение бактериальной загрязненности и уменьшение местных признаков воспаления, сокращение количества послеоперационных осложнений и средней продолжительности стационарного лечения. The author has examined 113 patients with the syndrome of the diabetic foot. One group of patients underwent traditional treatment, another one was added galvanization of the lower extremities, whereas the treatment was combined with intratissue electrophoresis of berlithion on the lower extremities in the third group. The most favourable course and treatment efficacy was noted in the third group of patients. An evaluation of the efficacy of treating has demonstrated a positive effect on the system of hemocoagulation and fibrinolysis, an improvement of the dynamics of the cytologic feature of wound impression smears, a somewhat accelerated wound repair, a more rapid decrease of their bacterial contamination and disappearance of local signs of inflammation, a reduction of the number of postoperative complications and the average term of inpatient treatment

Treatment of persistent postoperative pareses with galvanic current in peritonitis and acute intestinal obstruction

В експерименті на собаках вивчено дію постійного струму на перистальтику кишечнику, розроблено та впроваджено в практику нові методи лікування стійких парезів у ранньому післяопераційному періоді при гострій кишковій непрохідності та перитоніті, наведена порівняльна характеристика ефективності запропонованих і загальноприйнятих методів лікування.В эксперименте изучено действие постоянного тока на перистальтику кишечника, разработаны два метода лечения стойких парезов в раннем послеоперационном периоде при острой кишечной непроходимости и перитоните, представлена сравнительная характеристика эффективности предложенных и общепринятых методов.The action of constant current on the intestinal peristalsis in an experiment on dogs, new methods of treating persistent pareses at an early stage of the postoperative period in acute intestinal obstruction and peritonitis have been developed and introduced into practice, a comparative characteristic of the efficacy of the proposed and generally accepted treatment modes has been adduced

Non-Standard Errors

In statistics, samples are drawn from a population in a data-generating process (DGP). Standard errors measure the uncertainty in sample estimates of population parameters. In science, evidence is generated to test hypotheses in an evidence-generating process (EGP). We claim that EGP variation across researchers adds uncertainty: non-standard errors. To study them, we let 164 teams test six hypotheses on the same sample. We find that non-standard errors are sizeable, on par with standard errors. Their size (i) co-varies only weakly with team merits, reproducibility, or peer rating, (ii) declines significantly after peer-feedback, and (iii) is underestimated by participants